“Metabolic Reprogramming” in Ovarian Cancer Cells Resistant to Cisplatin

E-ISSN： 1873-5576|11|2|226-235

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.11, Iss.2, 2011-02, pp. : 226-235

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Synthetic Naphthoflavonoids Showing Inhibitory Effects on Clonogenicity against Cisplatin-Resistant A2780/Cis Human Ovarian Cancer Cells

Letters in Drug Design & Discovery, Vol. 12, Iss. 8, 2015-10 ,pp. : 628-639

Bentham Science Publishers

Access to resources Recommend Favorite

Characterization of the cell growth inhibitory effects of a novel DNA-intercalating bipyridyl-thiourea-Pt(II) complex in cisplatin-sensitive and—resistant human ovarian cancer cells

By Marverti Gaetano Ligabue Alessio Montanari Monica Guerrieri Davide Cusumano Matteo Pietro Maria Troiano Leonarda Vono Elena Iotti Stefano Farruggia Giovanna Wolf Federica Monti Maria Frassineti Chiara

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 73-86

Springer Publishing Company

Access to resources Recommend Favorite

Mitochondrial Mechanisms of Metabolic Reprogramming in Proliferating Cells

Current Medicinal Chemistry, Vol. 22, Iss. 20, 2015-01 ,pp. : 2493-2504

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment of platinum-resistant ovarian cancer

By Trimble Edward L Wright John Christian Michaele C

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 8, 2001-08 ,pp. : 1299-1306

Informa Healthcare

Access to resources Recommend Favorite

Paclitaxel vs cyclophosphamide, + cisplatin, for ovarian cancer

Inpharma, Vol. 1, Iss. 1581, 2007-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite